Enhanced anti-tumor therapeutic efficacy of DNA vaccine by fusing the E7 gene to BAFF in treating human papillomavirusassociated cancer

Oncotarget

Volumn 8, Issue 20, 2017, Pages 33024-33036

  Wu, Chao Chih ^a   Wu, Fang Cih ^a,c   Hsu, Yun Tin ^a   Hsiao, Yu Chia ^a   Yang, Yuh Cheng ^a   Chang, C Allen ^c   Chang, Chih Long ^a,b  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b MACKAY MEDICAL COLLEGE   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

BAFF; DNA vaccine

Indexed keywords

B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR E7 FUSED DNA VACCINE; DNA VACCINE; GAMMA INTERFERON; PROTEIN E7; UNCLASSIFIED DRUG; CANCER VACCINE; FUSION PROTEIN; TNFSF13B PROTEIN, HUMAN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; C57BL 6 MOUSE; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENDOPLASMIC RETICULUM; FEMALE; FLUORESCENCE MICROSCOPY; GENE FUSION; GENE GUN IMMUNIZATION; MALIGNANT NEOPLASM; MOUSE; NONHUMAN; PROMOTER REGION; TUMOR VOLUME; WART VIRUS; ANIMAL; DRUG SCREENING; GENETICS; HUMAN; IMMUNOLOGY; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; TUMOR CELL LINE; VIROLOGY;

ANIMALS; B-CELL ACTIVATING FACTOR; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; RECOMBINANT FUSION PROTEINS; VACCINES, DNA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85019213717     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.16032     Document Type: Article

References (39)

1. Fioretti D, Iurescia S, Fazio VM, Rinaldi M. DNA vaccines: developing new strategies against cancer. Journal of biomedicine & biotechnology. 2010; 2010:174378
2. Lowe DB, Shearer MH, Jumper CA, Kennedy RC. Towards progress on DNA vaccines for cancer. Cellular and molecular life sciences. 2007; 2391-2403
3. Cui Z. DNA vaccine. Advances in genetics. 2005; 54:257-289
4. Perales MA, Yuan J, Powel S, Gallardo HF, Rasalan TS, Gonzalez C, Manukian G, Wang J, Zhang Y, Chapman PB. Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. Molecular Therapy. 2008; 16:2022-2029
5. Chen SA, Tsai MH, Wu FT, Hsiang A, Chen YL, Lei HY, Tzai TS, Leung HW, Jin YT, Hsieh CL, Hwang LH, Lai MD. Induction of antitumor immunity with combination of HER2/neu DNA vaccine and interleukin 2 gene-modified tumor vaccine. Clinical cancer research. 2000; 6:4381-4388
6. Kutzler MA, Weiner DB. Developing DNA vaccines that call to dendritic cells. The Journal of clinical investigation. 2004; 114:1241-1244
7. Akbari O, Panjwani N, Garcia S, Tascon R, Lowrie D, Stockinger B. DNA vaccination: transfection and activation of dendritic cells as key events for immunity. The Journal of experimental medicine. 1999; 189:169-178
8. Lin K, Roosinovich E, Ma B, Hung CF, Wu TC. Therapeutic HPV DNA vaccines. Immunologic research. 2010; 47:86-112
9. Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Ling M, Wu TC. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. Journal of Clinical Investigation. 2001; 108:669-678
10. Stevenson FK, Mander A, Chudley L, Ottensmeier CH. DNA fusion vaccines enter the clinic. Cancer Immunology, Immunotherapy. 2011; 60:1147-1151
11. Mizrahi K, Askenasy N. Physiological functions of TNF family receptor/ligand interactions in hematopoiesis and transplantation. Blood. 2014
12. Haider S, Knöfler M. Human tumour necrosis factor: physiological and pathological roles in placenta and endometrium. Placenta. 2009; 30:111-123
13. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Archives of biochemistry and biophysics. 2008; 473:139-146
14. Juhász K, Buzás K, Duda E. Importance of reverse signaling of the TNF superfamily in immune regulation. Expert review of clinical immunology. 2013; 9:335-348
15. Batten M, Groom J, Cachero TG, Qian F, Schneider P, Tschopp J, Browning JL, Mackay F. BAFF mediates survival of peripheral immature B lymphocytes. The Journal of experimental medicine. 2000; 192:1453-1466
16. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nature Reviews Immunology. 2003; 3:745-756
17. Chen Q, Zhu G, Wang R, Zhang J, He G. Adjuvant effect of CD40 on H5N1 DNA vaccine in mice. Archives of virology. 2014; 159:1359-1364
18. Du X, Zheng G, Jin H, Kang Y, Wang J, Xiao C, Zhang S, Zhao L, Chen A Wang B. The adjuvant effects of co-stimulatory molecules on cellular and memory responses to HBsAg DNA vaccination. The journal of gene medicine. 2007; 9:136-146
19. Chen Y, Usherwood EJ, Surman SL, Hogg TL, Woodland DL. Long-term CD8+ T cell memory to Sendai virus elicited by DNA vaccination. Journal of general virology. 1999; 80:1393-1399
20. Rolink AG, Tschopp J, Schneider P, Melchers F. BAFF is a survival and maturation factor for mouse B cells. European journal of immunology. 2002; 32:2004-2010
21. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. The Journal of experimental medicine. 1999; 189:1747-1756
22. Rolink AG, Melchers F. BAFFled B cells survive and thrive: roles of BAFF in B-cell development. Current opinion in immunology. 2002; 14:266-275
23. Huard B, Schneider P, Mauri D, Tschopp J, French LE. T cell costimulation by the TNF ligand BAFF. The Journal of Immunology. 2001; 167:6225-6231
24. Kanagavelu S, Termini JM, Gupta S, Raffa FN, Fuller KA, Rivas Y, Philip S, Kornbluth RS, Stone GW. HIV-1 Adenoviral Vector Vaccines Expressing Multi-Trimeric BAFF and 4-1BBL Enhance T Cell Mediated Anti-Viral Immunity. PLoS One. 2014; 9:e90100
25. Kanagavelu SK, Snarsky V, Termini JM, Gupta S, Barzee S, Wright JA, Khan WN, Kornbluth RS, Stone GW. Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine. Vaccine. 2012; 30:691-702
26. Melchers M, Bontjer I, Tong T, Chung NP, Klasse PJ, Eggink D, Montefiori DC, Gentile M, Cerutti A, Olson WC. Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses. Journal of virology. 2012; 86:2488-2500
27. Kitamura D, Roes J, Kühn R, Rajewsky K. AB cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin μ chain gene. 1991
28. Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nature Reviews Cancer. 2008; 8:108-120
29. Gupta S, Termini JM, Raffa FN, Williams CA, Kornbluth RS, Stone GW. Vaccination with a fusion protein that introduces HIV-1 Gag antigen into a multitrimer CD40L construct results in enhanced CD8+ T cell responses and protection from viral challenge by vaccinia-Gag. Journal of virology. 2014; 88:1492-1501
30. Khanna R, Burrows SR, Argaet V, Moss DJ. Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumour cell line. International immunology. 1994; 6:639-645
31. Fu T-M, Mylin LM, Schell TD, Bacik I, Russ G, Yewdell JW, Bennink JR, Tevethia SS. An endoplasmic reticulumtargeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope. Journal of virology. 1998; 72:1469-1481
32. Ciernik IF, Berzofsky JA, Carbone DP. Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. The Journal of Immunology. 1996; 156:2369-2375
33. Boyle JS, Koniaras C, Lew AM. Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization. International immunology. 1997; 9:1897-1906
34. Lund LH, Andersson K, Zuber B, Karlsson A, Engström G, Hinkula J, Wahren B, Winberg G. Signal sequence deletion and fusion to tetanus toxoid epitope augment antitumor immune responses to a human carcinoembryonic antigen (CEA) plasmid DNA vaccine in a murine test system. Cancer gene therapy. 2003; 10:365-376
35. Bacík I, Snyder HL, Antón LC, Russ G, Chen W, Bennink JR, Urge L, Otvos L, Dudkowska B, Eisenlohr L. Introduction of a Glycosylation Site into a Secreted Protein Provides Evidence for an Alternative Antigen Processing Pathway: Transport of Precursors of Major Histocompatability Complex Class I-Restricted Peptides from the Endoplasmic Reticulum to the Cytosol. The Journal of experimental medicine. 1997; 186:479-487
36. Snyder HL, Bacík I, Bennink JR, Kearns G, Behrens TW, Bächi T, Orlowski M, Yewdell JW. Two novel routes of transporter associated with antigen processing (TAP)-independent major histocompatibility complex class I antigen processing. The Journal of experimental medicine. 1997; 186:1087-1098
37. Gil-Torregrosa BC, Castano AR, Del Val M. Major histocompatibility complex class I viral antigen processing in the secretory pathway defined by the trans-Golgi network protease furin. The Journal of experimental medicine. 1998; 188:1105-1116
38. Asano MS, Ahmed R. CD8 T cell memory in B celldeficient mice. The Journal of experimental medicine. 1996; 183:2165-2174
39. Wang TL, Ling M, Shih IM, Pham T, Pai SI, Lu Z, Kurman RJ, Pardoll DM, Wu TC. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene therapy. 2000; 7:726-733